BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 33984327)

  • 1. Tanshinone IIA sensitizes TRAIL-induced apoptosis in glioblastoma through inducing the expression of death receptors (and suppressing STAT3 activation).
    Zhou X; Lv L; Tan Y; Zhang Z; Wei S; Xiao S
    Brain Res; 2021 Sep; 1766():147515. PubMed ID: 33984327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tanshinone IIA induces TRAIL sensitization of human lung cancer cells through selective ER stress induction.
    Kim EO; Kang SE; Im CR; Lee JH; Ahn KS; Yang WM; Um JY; Lee SG; Yun M
    Int J Oncol; 2016 May; 48(5):2205-12. PubMed ID: 26983803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Celastrol enhances TRAIL-induced apoptosis in human glioblastoma via the death receptor pathway.
    Cha Z; Cheng J; Xiang H; Qin J; He Y; Peng Z; Jia J; Yu H
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):719-728. PubMed ID: 31281953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes.
    Guo L; Fan L; Pang Z; Ren J; Ren Y; Li J; Chen J; Wen Z; Jiang X
    J Control Release; 2011 Aug; 154(1):93-102. PubMed ID: 21609741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells.
    Yan S; Qu X; Xu C; Zhu Z; Zhang L; Xu L; Song N; Teng Y; Liu Y
    J Cancer Res Clin Oncol; 2012 Aug; 138(8):1279-89. PubMed ID: 22447040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tanshinone IIA inhibits the growth, attenuates the stemness and induces the apoptosis of human glioma stem cells.
    Yang L; Guo H; Dong L; Wang L; Liu C; Wang X
    Oncol Rep; 2014 Sep; 32(3):1303-11. PubMed ID: 24970314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azithromycin enhances anticancer activity of TRAIL by inhibiting autophagy and up-regulating the protein levels of DR4/5 in colon cancer cells in vitro and in vivo.
    Qiao X; Wang X; Shang Y; Li Y; Chen SZ
    Cancer Commun (Lond); 2018 Jul; 38(1):43. PubMed ID: 29970185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuciferine inhibits the progression of glioblastoma by suppressing the SOX2-AKT/STAT3-Slug signaling pathway.
    Li Z; Chen Y; An T; Liu P; Zhu J; Yang H; Zhang W; Dong T; Jiang J; Zhang Y; Jiang M; Yang X
    J Exp Clin Cancer Res; 2019 Mar; 38(1):139. PubMed ID: 30922391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of microRNA135a-3p and death receptor 5 plays a critical role in Tanshinone I sensitized prostate cancer cells to TRAIL induced apoptosis.
    Shin EA; Sohn EJ; Won G; Choi JU; Jeong M; Kim B; Kim MJ; Kim SH
    Oncotarget; 2014 Jul; 5(14):5624-36. PubMed ID: 25015549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor-related apoptosis-inducing ligand and induces an alternative cell death pathway.
    Badr CE; Wurdinger T; Nilsson J; Niers JM; Whalen M; Degterev A; Tannous BA
    Neuro Oncol; 2011 Nov; 13(11):1213-24. PubMed ID: 21757445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
    Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
    Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of ataxia telangiectasia mutated kinase activity enhances TRAIL-mediated apoptosis in human melanoma cells.
    Ivanov VN; Zhou H; Partridge MA; Hei TK
    Cancer Res; 2009 Apr; 69(8):3510-9. PubMed ID: 19351839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Snake venom toxin from Vipera lebetina turanica sensitizes cancer cells to TRAIL through ROS- and JNK-mediated upregulation of death receptors and downregulation of survival proteins.
    Park MH; Jo M; Won D; Song HS; Song MJ; Hong JT
    Apoptosis; 2012 Dec; 17(12):1316-26. PubMed ID: 23007278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR-targeted diphtheria toxin stimulates TRAIL killing of glioblastoma cells by depleting anti-apoptotic proteins.
    Horita H; Thorburn J; Frankel AE; Thorburn A
    J Neurooncol; 2009 Nov; 95(2):175-184. PubMed ID: 19449148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis.
    Murphy ÁC; Weyhenmeyer B; Noonan J; Kilbride SM; Schimansky S; Loh KP; Kögel D; Letai AG; Prehn JH; Murphy BM
    Apoptosis; 2014 Apr; 19(4):629-42. PubMed ID: 24213561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
    Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells.
    Dorsey JF; Mintz A; Tian X; Dowling ML; Plastaras JP; Dicker DT; Kao GD; El-Deiry WS
    Mol Cancer Ther; 2009 Dec; 8(12):3285-95. PubMed ID: 19996278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
    Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of HSP70 expression sensitizes NSCLC cell lines to TRAIL-induced apoptosis by upregulating DR4 and DR5 and downregulating c-FLIP-L expressions.
    Zhuang H; Jiang W; Zhang X; Qiu F; Gan Z; Cheng W; Zhang J; Guan S; Tang B; Huang Q; Wu X; Huang X; Jiang W; Hu Q; Lu M; Hua ZC
    J Mol Med (Berl); 2013 Feb; 91(2):219-35. PubMed ID: 22948392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer.
    Guo L; Fan L; Ren J; Pang Z; Ren Y; Li J; Wen Z; Qian Y; Zhang L; Ma H; Jiang X
    Int J Nanomedicine; 2012; 7():1449-60. PubMed ID: 22619505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.